Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
Delivery & Returns Free Delivery Same day dispatch on all orders placed before 14:30 (GMT) and free UK delivery on orders over 50 Click and Collect Click and Collect is available for customers who live within 25 miles of our Driffield warehouse International Delivery European delivery options vary by country
MT received lecture fees from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sumitomo, and Mitsubishi Tanabe and received subsidies from Super Light Water, TAKAGI, Roche DC, and LifeScan
Expected Weight-Loss Results Weight loss with GLP-1 medications is steady and progressive rather than sudden
Separate and combined effects of GIP and GLP-1 infusions on bone metabolism in overweight men without diabetes
US$ 22.79
US$ 24.17
US$ 24.48
US$ 21.99
US$ 29.09
US$ 21.92
US$ 20.81
US$ 21.64
US$ 28.34
